Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 46%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is launching its first commercial product, apitegromab, which treats Spinal Muscular Atrophy, and has received positive feedback from the FDA regarding its manufacturing facilities. This milestone, along with potential European approval in mid-2026, positions the company for significant revenue growth potential. Additionally, the company is also developing a subcutaneous formulation of apitegromab to expand patient access, and has a diverse pipeline targeting other neuromuscular diseases. Overall, with confidence in the company's manufacturing issues being resolved, we anticipate a successful launch of apitegromab and see significant upside potential for the company.

Bears say

Scholar Rock Holding is projected to have a near-term BLA resubmission and potential FDA approval for apitegromab, a significant regulatory de-risking event that could support a 2026 launch and positive launch dynamics. This is further supported by the company's progress on early-stage programs and additional fill-finish facility, but risks such as weight-based pricing dynamics and sluggish initial uptake could temper the initial trajectory. Given the projected launch and potential approval, a neutral outlook may be more appropriate for investors evaluating the company's potential.

SRRK has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 46% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 13 analysts, SRRK has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.